Literature DB >> 12601699

Progressive neocortical damage in epilepsy.

Rebecca S N Liu1, Louis Lemieux, Gail S Bell, Alexander Hammers, Sanjay M Sisodiya, Philippa A Bartlett, Simon D Shorvon, Josemir W A S Sander, John S Duncan.   

Abstract

Our objective was to determine the pattern and extent of generalized and focal neocortical atrophy that develops in patients with epilepsy and the factors associated with such changes. As part of a prospective, longitudinal follow-up study of 122 patients with chronic epilepsy, 68 newly diagnosed patients, and 90 controls, serial magnetic resonance imaging scans were obtained 3.5 years apart. Image subtraction was used to identify diffuse and focal neocortical change that was quantified with a regional brain atlas and a fully automated segmentation algorithm. New focal or generalized neocortical volume losses were identified in 54% of patients with chronic epilepsy, 39% of newly diagnosed patients and 24% of controls. Patients with chronic epilepsy were significantly more likely to develop neocortical atrophy than control subjects. The increased risk of cerebral atrophy in epilepsy was not related to a history of documented seizures. Risk factors for neocortical atrophy were age and multiple antiepileptic drug exposure. Focal and generalized neocortical atrophy commonly develops in chronic epilepsy. Neocortical changes seen in a quarter of our control group over 3.5 years were likely to reflect physiological changes. Our results show that ongoing cerebral atrophy may be widespread and remote from the putative epileptic focus, possibly reflecting extensive networks and interconnections between cortical regions.

Entities:  

Mesh:

Year:  2003        PMID: 12601699     DOI: 10.1002/ana.10463

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  35 in total

Review 1.  Early epilepsy surgery.

Authors:  Samuel Wiebe
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

2.  Early Seizure Onset and Brain Development: The Emerging Picture.

Authors:  Michael Duchowny
Journal:  Epilepsy Curr       Date:  2003-07       Impact factor: 7.500

3.  The role of MRI in localisation of epileptogenic foci: how far have we come?

Authors:  Roland Wiest; Barbara Schauble
Journal:  Neuroradiology       Date:  2005-11       Impact factor: 2.804

Review 4.  Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy.

Authors:  Bruce Hermann; Michael Seidenberg; Mark Sager; Cynthia Carlsson; Barry Gidal; Raj Sheth; Paul Rutecki; Sanjay Asthana
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

5.  Effects of an acute seizure on associative learning and memory.

Authors:  Andrew J Holley; Joaquin N Lugo
Journal:  Epilepsy Behav       Date:  2015-12-03       Impact factor: 2.937

6.  Extratemporal damage in temporal lobe epilepsy: magnetization transfer adds information to volumetric MR imaging.

Authors:  P R B Diniz; T R Velasco; C E G Salmon; A C Sakamoto; J P Leite; A C Santos
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-01       Impact factor: 3.825

7.  A Lighter Shade of Gray: Is Temporal Lobe Epilepsy a Progressive Gray Matter Disorder?

Authors:  Frank Gilliam
Journal:  Epilepsy Curr       Date:  2017 Jan-Feb       Impact factor: 7.500

8.  Voxel-based optimized morphometry (VBM) of gray and white matter in temporal lobe epilepsy (TLE) with and without mesial temporal sclerosis.

Authors:  Suzanne G Mueller; Kenneth D Laxer; Nathan Cashdollar; Shannon Buckley; Crystal Paul; Michael W Weiner
Journal:  Epilepsia       Date:  2006-05       Impact factor: 5.864

Review 9.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

10.  Brain structure and aging in chronic temporal lobe epilepsy.

Authors:  Kevin Dabbs; Tara Becker; Jana Jones; Paul Rutecki; Michael Seidenberg; Bruce Hermann
Journal:  Epilepsia       Date:  2012-04-03       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.